New Zealand markets closed

DiaMedica Therapeutics Inc. (DMAC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.9500-0.1000 (-3.28%)
At close: 04:00PM EDT
2.9300 -0.02 (-0.68%)
After hours: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 111.99M
Enterprise value 65.86M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.42
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.96

Trading information

Stock price history

Beta (5Y monthly) 1.73
52-week change 3-32.95%
S&P500 52-week change 322.55%
52-week high 34.4500
52-week low 31.9382
50-day moving average 32.7639
200-day moving average 32.7166

Share statistics

Avg vol (3-month) 352.73k
Avg vol (10-day) 3148.74k
Shares outstanding 537.96M
Implied shares outstanding 637.96M
Float 823.81M
% held by insiders 126.64%
% held by institutions 124.00%
Shares short (14 Jun 2024) 4128.37k
Short ratio (14 Jun 2024) 46.55
Short % of float (14 Jun 2024) 40.54%
Short % of shares outstanding (14 Jun 2024) 40.34%
Shares short (prior month 15 May 2024) 4128.56k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 315 Nov 2018
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 315 Nov 2018

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-33.79%
Return on equity (ttm)-52.50%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -21.46M
Net income avi to common (ttm)-19.26M
Diluted EPS (ttm)-0.5400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)46.52M
Total cash per share (mrq)1.23
Total debt (mrq)380k
Total debt/equity (mrq)0.82%
Current ratio (mrq)18.14
Book value per share (mrq)1.22

Cash flow statement

Operating cash flow (ttm)-20.29M
Levered free cash flow (ttm)-11.83M